Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3-16 mg taselisib once daily capsule). Taselisib pharmacokinetics w...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Discov
Main Authors: Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K., Wilson, Timothy R., Ware, Joseph A., Sanabria Bohorquez, Sandra M., Savage, Heidi M., Sampath, Deepak, Salphati, Laurent, Lin, Ray S., Jin, Huan, Parmar, Hema, Hsu, Jerry Y., Von Hoff, Daniel D., Baselga, Jose
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501742/
https://ncbi.nlm.nih.gov/pubmed/28331003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1080
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker